Market News How it works Learn FAQ
| AXG 0.0378 -29.74% | SHFS 0.1113 18.40% | DVLT 0.069 -48.04% | XXII 0.1022 15.61% | NEXR 0.5454 21.77% | SOFI 16.4 13.42% | WFF 0.0601 -33.07% | NU 12.4 -1.51% | NVD 3.93 -1.50% | SPCX 148.58 1.14% | SOXL 101.08 11.69% | EWZ 34.3 0.45% | INTC 93.74 3.61% | NVDA 217.94 0.90% | BBD 2.91 -0.51% | SOXS 42.495 -11.43% | JBLU 2.82 18.99% | GRAB 2.72 0.37% | GPUS 0.2126 19.10% | VALE 11.84 -1.33% | SNTI 0.1867 6.62% | NOK 8.89 3.30% | HYG 77.6 0.52% | AAL 12.61 3.36% | BITO 10.79 1.27% | CRWV 59.57 7.94% | TSLL 11.63 8.09% | RCT 0.0632 -23.58% | META 620.19 -1.64% | TQQQ 71.05 3.83% | QID 13.86 -2.53% | STLA 4.14 1.47% | NFLX 62.52 -2.16% | TSLG 5.82 8.18% | BA 168.18 -10.69% | IREN 27.44 7.90% | T 20.94 0.46% | PLUG 1.4 2.19% | BRAI 3.31 56.13% | TSLA 407.46 4.04% | CIFR 8.48 9.99% | ONDS 6.65 7.95% | RWM 14.34 -1.10% | F 11.71 1.12% | RIG 6.46 -1.07% | XP 15.96 1.62% | ITUB 7.67 -0.39% | SNAP 6.06 -4.42% | KORU 11.85 8.82% | WULF 12.66 5.68%
CRCardiol Therapeutics Inc. logo

Cardiol Therapeutics Inc. (CRDL)

NASDAQ Capital Market · Currency in USD
$1.14 ▲ +0.02 (+1.79%)
At close: Oct 27, 4:00 PM ET. Market closed.
$1.18 ▲ +0.04 (+3.47%)
After hours: Oct 27, 4:11 PM ET

Summary

Previous Close
$1.12
Open
$1.13
Day's Range
$1.13 – $1.16
52 Week Range
$0.88 – $2.34
Volume
312,239
Avg. Volume
1,211,659
Market Cap
$137.55M
Beta (5Y Monthly)
0.52
PE Ratio (TTM)
--
EPS (TTM)
-$0.30
Earnings Date
Nov 12, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$8.00

Profile: Cardiol Therapeutics Inc.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Full-time employees
18
CEO
David G. Elsley

Cardiol Therapeutics Inc. is a clinical-stage life sciences firm dedicated to discovering and advancing anti-fibrotic and anti-inflammatory therapies for cardiovascular disease (CVD). Its leading candidate, CardiolRx, is currently undergoing a multi-national, randomized, double-blind, placebo-controlled Phase II/III study. Furthermore, the company is developing a subcutaneous version of CardiolRx, aimed at addressing the cardiac fibrosis and inflammation linked to the onset and progression of heart failure.

Earnings

Next report: Thu, Nov 12, 2026
EPS estimate -$0.06
DateEst.Actual
Aug 13, 2026-$0.09-$0.04Beat
May 11, 2026-$0.07-$0.07Beat
Mar 30, 2026-$0.09-$0.05Beat
Nov 13, 2025-$0.09-$0.09Beat
Aug 14, 2025-$0.11-$0.07Beat
May 14, 2025-$0.09-$0.07Beat

Analyst view

Consensus price target
$8.00 ▲ +601.8%
Range $8.00 – $8.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on CRDL and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.